

Form PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 10-95)		ATTORNEY'S DOCKET NUMBER 702-991768
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 09/424815
INTERNATIONAL APPLICATION NO. PCT/NL98/00311	INTERNATIONAL FILING DATE 29.05.98 (May 18, 1998)	PRIORITY DATES CLAIMED 29.05.97 (May 29, 1997)
TITLE OF INVENTION ANTIMICROBIAL PEPTIDES DERIVED FROM UBIQUICIDINE		
APPLICANT(S) FOR DO/EO/US Petrus Hendricus NIBBERING, Pieter Sicco HIEMSTRA, Maria Theodora VAN DEN BARSELAAR, Ernest Karel Jacob PAUWELS and Rolf Ide Johannes FEITSMA		
<p>Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:</p> <ol style="list-style-type: none"> <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). <input checked="" type="checkbox"/> has been transmitted by the International Bureau. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). <input type="checkbox"/> have been transmitted by the International Bureau. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. <input checked="" type="checkbox"/> have not been made and will not be made. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). <p>Items 11. to 16. below concern document(s) or information included:</p> <ol style="list-style-type: none"> <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. <input type="checkbox"/> A substitute specification. <input type="checkbox"/> A change of power of attorney and/or address letter. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> Letter Recognizing Attorneys WO 98/54314-Front Page with Abstract, Specification, Claims, Drawings and Search Report (47 pp.) International Preliminary Examination Report with Annex (9 pp.) 		

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 1.5em; font-weight: bold; text-align: center;">09/424815</div>	INTERNATIONAL APPLICATION NO. PCT/NL98/00311	ATTORNEY'S DOCKET NUMBER 702-991786
--	---	--

17. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO..... \$840.00 International preliminary examination fee paid to USPTO (37 CFR 1.482)..... \$670.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2))..... \$760.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$970.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)..... \$96.00 <div style="text-align: right; font-weight: bold;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>	CALCULATIONS PTO USE ONLY <div style="border: 1px solid black; height: 100px; margin-top: 10px;"></div>
--	---

Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	<div style="border: 1px solid black; padding: 5px;">\$ 840.00</div> <div style="border: 1px solid black; padding: 5px;">\$ 130.00</div>
--	---

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	26 - 20	6	X \$18.00	\$ 108.00	
Independent claims	10 - 3 =	7	X \$78.00	\$ 546.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	\$ 0.00	
TOTAL OF ABOVE CALCULATIONS =				\$ 1,624.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).				\$ 0.00	
SUBTOTAL =				\$ 1,624.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 0.00	
TOTAL NATIONAL FEE =				\$ 1,624.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$ 0.00	
TOTAL FEES ENCLOSED =				\$ 1,624.00	
				Amount to be:	\$
				refunded	
				charged	\$

a. ☒ A check in the amount of \$ 1,624.00 to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees.
A duplicate copy of this sheet is enclosed.

c. ☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 23-0650. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:
 Barbara E. Johnson
 700 Koppers Building
 436 Seventh Avenue
 Pittsburgh, Pennsylvania 15219-1818
 Telephone: (412) 471-8815
 Facsimile: (412) 471-4094

SIGNATURE
 Barbara E. Johnson
 NAME
 31,198
 REGISTRATION NUMBER

09 / 4 24 815

420 Rec'd PCT/PTO 29 NOV 1999

PATENT APPLICATION

Attorney Docket 702-991768

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :

PETRUS HENDRICUS NIBBERING, : ANTIMICROBIAL PEPTIDES
PIETER SICCO HIEMSTRA, : DERIVED FROM UBIQUICIDINE
MARIA THEODORA VAN DEN BARSELAAR, :
ERNEST KAREL JACOB PAUWELS :
and ROLF IDE JOHANNES FEITSMA :

International Application :
No. PCT/NL98/00311 :

International Filing Date :
29 May 1998 :

Priority Date Claimed :
29 May 1997 :

Serial No. Not Yet Assigned :
Filed Concurrently Herewith :

Pittsburgh, Pennsylvania

November 29, 1999

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

Prior to initial examination, please amend the above-identified patent application as follows:

IN THE CLAIMS:

Original claims 1-24 were replaced during Chapter II proceedings in a letter dated 9 June 1999 with claims 1-26. Please cancel original claims 1-24, amend amended claims 4, 5-7, 9, 17-20, 22 and 26, cancel amended claim 1 and add new claim 27 as follows:

Cancel amended claim 1.

Claim 4, line 1, cancel "claims 2 and" and insert therefor --claim 2--.

Claim 4, line 2, cancel "3".

5. (Amended) Derivative of ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a continuous series of at least 3[, preferably at least 8] amino acids from the amino acid sequence of ubiquicidine:

5 KVGHSLARAGKVRGQTPKVAQEKKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS, which derivative has an amino acid sequence which is at least partly the reverse of the amino acid sequence of the corresponding original peptide [(fragment) (so-called "(partial) reverse peptide")].

6. (Amended) Derivative of a ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a continuous series of at least 3[, preferably at least 8] amino acids from the amino acid sequence of ubiquicidine:

5 KVGHSLARAGKVRGQTPKVAQEKKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS, wherein at least one of the amino acids from the original peptide (fragment) is replaced by a stereoisomer of that amino acid.

7. (Amended) Derivative of ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a continuous series of at least 3[, preferably at least 8] amino acids from the amino acid sequence of ubiquicidine:

5 KVGHSLARAGKVRGQTPKVAQEKKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS, wherein the original amino acid chain is extended at one or both ends thereof with one or more groups, such as D-amino acids, protecting against degradation.

9. (Amended) Hybrid molecule, comprising a cationic peptide with an antimicrobial action and/or a peptide fragment as claimed in [claims 2-4 and/or a derivative thereof as claimed in claims 5-8] claim 2, and one or more effector molecules.

17. (Amended) Derivatives as claimed in [claims 5-8] claim 5 for use in the diagnostics, prophylaxis or therapy of infections in humans and animals.

18. (Amended) Hybrid molecules as claimed in [claims 9-14] claim 9 for use in the diagnostics, prophylaxis, therapy or monitoring of infections in humans and animals.

19. (Amended) Peptide fragments as claimed in claim 15 [or 16, derivatives as claimed in claim 17 or hybrid molecules as claimed in claim 18] or derivative or hybrid molecules thereof, wherein the microbial infections are caused by pathogenic Gram-
5 positive (*Staphylococcus aureus*, *Listeria monocytogenes* including antibiotic-resistant strains of *S.aureus* (also called Multidrug Resistant *S.aureus* (MRSA)) and Gram-negative ((antibiotic-resistant) *Klebsiella pneumoniae*, *Escherichia coli*, enterococci and *Salmonella typhimurium*) bacteria, micro-organisms difficult to
10 treat, such as *Mycobacterium avium* and *Mycobacterium fortuitum*, fungi, such as *Candida albicans*, *Cryptococcus neoformans* and *Aspergillus fumigatis*, viruses, in particular enveloped viruses, and parasites, such as *Trypanosoma cruzi* and *Toxoplasma gondii*.

20. (Amended) Antimicrobial agent, comprising at least a suitable quantity of one or more active components chosen from ubiquicidine, peptide fragments derived from ubiquicidine and comprising a continuous series of at least 3[, preferably at least 5 8] amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS,
[derivatives thereof as claimed in claims 5-8, hybrid molecules as claimed in claims 9-14,] optionally in the presence of one or more suitable excipients.

22. (Amended) Diagnostic agent, comprising a suitable quantity of one or more active components provided with a detectable label and chosen from ubiquicidine, peptide fragments derived from ubiquicidine and comprising a continuous series of at 5 least 3[, preferably at least 8] amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS,
[derivatives thereof as claimed in claims 5-8, hybrid molecules as claimed in claims 9-14] or derivative or hybrid molecules thereof.

26. (Amended) Method for preparing ubiquicidine, peptide fragments derived from ubiquicidine and comprising a continuous series of at least 3[, preferably at least 8] amino acids from the amino acid sequence of ubiquicidine:

5 KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVVPTFGKKKGPNANS,
[derivatives thereof as claimed in claims 5-8, hybrid molecules as claimed in claims 9-14] or derivative or hybrid molecules thereof

by transforming an animal egg-cell with a gene construct which codes for the ubiquicidine, peptide fragment, derivative or hybrid molecule, regenerating a transgenic animal from the transformed egg-cell and isolating the ubiquicidine, peptide fragment, derivative or hybrid molecule from a tissue or bodily fluid of the animal, for instance milk.

Add new claims 27 as follows:

--27. Hybrid molecule, comprising a cationic peptide with an antimicrobial action and/or a peptide fragment as claimed in claim 5 and one or more effector molecules.--

IN THE ABSTRACT:

After the claims, please insert a page containing the Abstract Of The Disclosure, which is attached hereto as a separately typed page.

REMARKS

The above amendments to the claims have been submitted herewith to conform the concurrently filed patent application to customary United States practice and to eliminate the multiple dependencies in the claims. Claim 1 has been canceled, claims 4, 5-7, 9, 17-20, 22 and 26 have been amended and claim 27 has been added to further define the invention.


An Abstract Of The Disclosure has been added as a separately typed page to be inserted after the claims.

Entry of this Preliminary Amendment and examination and allowance of pending claims 2-27 are respectfully requested.

Respectfully submitted,

WEBB ZIESENHEIM LOGSDON
ORKIN & HANSON, P.C.

By


Barbara E. Johnson, Reg. No. 31,198
Attorney for Applicants
700 Koppers Building
436 Seventh Avenue
Pittsburgh, PA 15219-1818
Telephone: (412) 471-8815
Facsimile: (412) 471-4094

ANTIMICROBIAL PEPTIDES DERIVED FROM UBIQUICIDINE

ABSTRACT OF THE DISCLOSURE

The invention relates to the use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals. A peptide fragment derived from ubiquicidine comprises for instance a preferably continuous series of at least 3, preferably at least 7-13 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVPFTFGKKKGPNA
NS. Hybrid molecules comprise for instance a cationic peptide with an antimicrobial action and/or a peptide fragment of ubiquicidine and/or a derivative thereof and one or more effector molecules.

1 420 Rec'd PCT/PTO 29 NOV 1999

ANTIMICROBIAL PEPTIDES DERIVED FROM UBIQUICIDINE

5 The present invention relates to the new medical use of a per se known peptide, which will be referred to as "ubiquicidine" in this application. The invention further relates to new peptide fragments derived from this peptide, optionally in modified form or provided with a (radioactive) label, and the use hereof in prophylaxis, therapy and diagnostics of infections in humans and animals. The invention also relates to new antimicrobial and diagnostic agents on the basis of the peptide, the peptide fragments and/or modified versions thereof, optionally in the form of combination preparations. Finally, the invention also provides a new method for preparing radioactively labelled peptides with antimicrobial activity.

15 In an increasing number of cases the use of what are called "classic" antibiotics is not sufficient for the treatment of infectious diseases. Many bacteria strains have built up resistance against the known classes of antibiotic and in the last thirty years no new classes of antibiotic have been discovered. There are few or no adequate agents against mycobacteria. And other microorganisms, such as fungi, and determined parasites are also sometimes difficult to treat with existing antimicrobial agents. In view of the above, a new class of antimicrobial agents is highly desirable.

25 At present, two new types of antimicrobial agents are attracting attention. On the one hand there are the carbohydrate-type agents. In addition, research is focusing on peptides, particularly (cationic) peptides, with antimicrobial activity. Cationic peptides contain a relatively large number of positively charged amino acids, such as arginine and lysine, and therefore carry a net positive charge, usually of at least +2, but often +4 or more. Antimicrobial peptides are an important component of the natural defence of most living organisms against infections. Many such antimicrobial peptides are

cationic. In humans and other mammals such peptides, such as the defensins, are an important protein-like constituent of for instance neutrophil granulocytes. These cells are already involved at a very early stage in the defence against micro-organisms and in acute inflammation reactions. In addition, such peptides are also produced by many other cells, including epithelial cells, which are strategically located in relation to invading micro-organisms.

10 In the research which resulted in the present invention, it was found that the per se known peptide FAU S30 (which has now been called "ubiquicidine" by the present inventors) has antimicrobial action. It was further found that peptide (fragments) derived from this peptide also have an antimicrobial action to a lesser or greater extent. These peptide (fragments) as such have not been described previously and are therefore still new.

On the basis of this conclusion, the present invention provides the use of ubiquicidine or optionally modified peptide (fragments) derived therefrom for preparing a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals.

The advantage of ubiquicidine and fragments thereof is that they not only have an antimicrobial and immunomodulating action, but that they also make their way in the body in targeted manner to the actual site of infection and accumulate there. These peptide (fragments) are therefore infection-seeking.

In this application "antimicrobial action" is understood to mean any inhibiting or otherwise negative effect on bacteria, viruses, protozoa, parasites and fungi.

"Immunomodulating action" is understood in this application to mean any stimulating effect on body cells of humans and/or animals involved in the defence against infections.

"Ubiquicidine" is understood in this application to mean a peptide of 6.654 kD with an amino acid sequence as shown in figure 1.

Peptide fragments derived from ubiquicidine comprise a preferably continuous series of at least 3, preferably

at least 8 amino acids from the amino acid sequence of ubiquicidine as shown in figure 1. For an average skilled person it is simple to ascertain whether a peptide fragment with a series of preferably continuous amino acids
5 chosen from the amino acid sequence of ubiquicidine does actually have antimicrobial activity and thus meets the requirements of the invention. A simple standard test for determining antimicrobial activity is for instance the
10 of the concentration of an antimicrobial agent which kills 99% of the micro-organisms (IC 99%). Designated by "peptide (fragments)" in this application are therefore all amino acid chains which are smaller than the ubiquicidine itself, but the amino acid sequence of which is to
15 be found, preferably continuously, in the ubiquicidine. The length of such peptide (fragments) can vary from 3 to 58 amino acids, wherein possible extra amino acids added as modification are not included.

Examples of peptide (fragments) are the peptides of
20 which the sequence is shown in figure 1. Ubiquicidine (18-35)-D-alanine has as extra addition a D-alanine at both ends. Of the peptide fragments shown in figure 1, ubiquicidine (1-18), ubiquicidine (18-35) and ubiquicidine (29-41) are particularly recommended. In the above
25 described test the activity of these fragments lies around 1 μ M. This is a particularly good antimicrobial activity. In principle however, all the above defined peptides, which display some inhibiting action or other on micro-organisms, fall within the invention. Peptides
30 with an IC 99% of a maximum of 25 μ M, preferably a maximum of 10 μ M, most preferably a maximum of 1 μ M are however recommended.

In order to modify their activity, for instance to further increase it, or to inhibit or prevent degradation
35 by enzymes, particularly peptidases, both the peptide (ubiquicidine) and the fragments can be modified in different ways. Modification is any variation from the naturally occurring amino acid chain. Modifications may be mutual linking in reverse sequence of at least a part
40 of the amino acids of the peptide or a peptide fragment.

When all amino acids of a peptide (fragment) are thus reversed, this is referred to as "reverse peptide (fragment)".

One or more of the amino acids from the original peptide (fragment) can also be replaced by a stereoisomer of that amino acid. The L-isomers of amino acids occur in the body. The D-stereoisomers can be degraded much less easily by enzymes present in the body and bacterial enzymes. Such a modification ensures that the peptide (fragment) in the body remains intact longer and can exert its effect longer. A similar modification consists of extending the original amino acid chain at one or both ends with one or more groups protecting against degradation, such as D-amino acids, for instance D-alanine.

All the amino acid chains modified in the above described manner or varying in other manner from the corresponding native peptide (fragment) will be designated in this application with the term "derivative". These can be derivatives of the ubiquicidine as well as of fragments thereof.

The invention further relates to so-called "hybrid molecules", which comprise a (cationic) peptide with an antimicrobial action and/or a peptide fragment and/or a derivative thereof according to the invention together with one or more effector molecules. The effector molecule can assume different forms, such as an amino acid chain, which is capable of binding to a micro-organism and/or substances secreted by micro-organisms or expressed on the surface thereof. An example of such an effector molecule is an endotoxin-binding peptide.

Another type of effector molecule can consist of a virus protein. Such a virus protein/antimicrobial peptide can enter the host cell, in which the micro-organism for combatting is situated, in the known manner of a virus and the peptide can exert its antimicrobial action therein.

The effector molecule can further be a detectable label, such as a radionuclide, chosen from the group consisting of technetium 99m (Tc-99m), iodine 123 (I-123) and 131 (I-131), bromine 75 (B-75) and 76 (B-76), lead 203

(Pb-203), gallium 67 (Ga-67) and 68 (Ga-68), arsenic 72 (As-72), indium 111 (In-111), 113m (In-113m) and 114m (In-114m), ruthenium 97 (Ru-97), copper 62 (Cu-62), 64 (Cu-64) and 67 (Cu-67), iron 52 (Fe-52), manganese 52m (Mn-52m), chromium 51 (Cr-51), rhenium 186 (Re-186) and 188 (Re-188), terbium 161 (Tb-161) and yttrium 90 (Y-90). The radionuclide (also called "emitter") can also fulfil a curative function. Paramagnetic labels, such as fluorine 19 (F-19), sodium 23 (Na-23), phosphorus 31 (P-31), gadolinium 157 (Gd-157), manganese 55 (Mn-55), dysprosium 162 (Dy-162), chromium 52 (Cr-52) and iron 56 (Fe-56) can also be used.

According to the invention combinations of effector molecules can likewise be linked to the peptide. An example thereof are a cell-binding peptide and an emitter, wherein the cell-binding peptide and the antimicrobial peptide provide targeting of the hybrid molecule to the site of infection and the antimicrobial peptide and the emitter provide for treatment or diagnosis.

Hybrid molecules of this type which consist of an antimicrobial peptide, peptide fragment or derivative thereof and at least one effector molecule have not been described previously. The "hybrid molecules" according to the invention are not therefore limited to the ubiquicidine as antimicrobial peptide, but generally comprise hybrid molecules comprising a (cationic) peptide with antimicrobial activity and/or fragments and/or derivatives thereof. Examples of other such antimicrobial peptides are α - and β -defensins, protegrins, serprocidins, magainins, PR-39, cecropins and others (Martin et al. (1995) J. Leukocyte Biol. 58:128-136).

The invention relates to the variants of the peptide or fragments thereof comprehensively described above. These variants as well as the peptide and the fragments can also be designated collectively in this application as "peptide (fragments)".

The invention further relates to an antimicrobial agent comprising as active component ubiquicidine and/or peptide fragments thereof, derivatives of one of both and/or hybrid molecules containing at least ubiquicidine

or other antimicrobial cationic peptides and/or peptide fragments thereof and/or derivatives thereof for use in the diagnostics, prophylaxis, monitoring or therapy of infections.

5 The antimicrobial agent according to the invention can contain only the active component or take the form of a pharmaceutical composition in which one or more other carriers, diluents and the like are present. The agent and the composition can have different forms of adminis-
10 tration, such as for instance tablet, pill, capsule, injection, infusion, suppository, powder, suspension, solution, spray, emulsion, ointment, aerosol, plaster or cream and can be used for oral, anal, nasal, vaginal, intramuscular, subcutaneous, intravenous, intraperitoneal
15 or local (topical) administration or administration by means of a catheter via natural or artificial body openings. Other very specific examples of forms of administration are toothpaste, tooth varnish and catheters coated with the active compound. These latter have a
20 prophylactic action.

Compositions according to the invention can be prepared by combining (i.e. mixing, dissolving et cetera) of the active component(s) with pharmaceutically and pharmacologically acceptable excipients with a neutral
25 character (such as aqueous or non-aqueous solvents, stabilizers, emulsifiers, detergents, additives), and further, where necessary, colorants, aromatic substances and/or flavourings. The concentration of the active component(s) in a pharmaceutical composition can vary
30 between 0.001% and 100% (w/v), depending on the nature of the treatment and the manner of administering. The dose for administering likewise depends on the manner of administration and nature of the treatment. For the mouse for instance a dose of 1 to 10 $\mu\text{g/kg}$, for instance 4
35 $\mu\text{g/kg}$ body weight, is suitable. The compositions according to the invention are suitable for treatment of both humans and animals.

The invention further relates to the ubiquicidine, to peptide fragments thereof, to derivatives of one of
40 both and to hybrid molecules containing at least ubiqui-

cidine or other antimicrobial cationic peptides, and/or peptide fragments thereof and/or derivatives thereof for use in diagnostics, prophylaxis, therapy or monitoring of infections.

- 5 Infections, which can be treated with the agent are for instance disorders caused by pathogenic Gram-positive (Staphylococcus aureus, Listeria monocytogenes including antibiotic-resistant strains of S.aureus (also called Multidrug-Resistant S.aureus (MRSA))), and Gram-negative
- 10 ((antibiotic-resistant) Klebsiella pneumoniae, Escherichia coli, enterococci and Salmonella typhimurium) bacteria, micro-organisms difficult to treat such as Mycobacterium avium and Mycobacterium fortuitum, fungi such as Candida albicans, Cryptococcus neoformans and Aspergillus
- 15 fumigatis, viruses, in particular enveloped viruses, and parasites, such as Trypanosoma cruzi and Toxoplasma gondii. The use of the agent is however not limited to the infections stated here.

- Because the peptide (fragment) according to the
- 20 invention is infection-seeking, it can be applied very well in the diagnostics of infections and pathology related thereto. If provided with a detectable label, for instance a radioactive label such as technetium 99m, it is possible for instance by means of scintigraphy to
- 25 determine some time after administering where in the body the peptide (fragment) is situated. This will also be the site where the infection for treatment is situated. Such a labelled peptide (fragment) therefore has a dual purpose. Not only is demonstrated where the infection is
- 30 situated, but the peptide (fragment) will also exert an antibiotic action due to its presence at the site and thus reduce the infection. In this manner the effect of the treatment can also be followed by looking at the localization of the peptide in time. This is called
- 35 "monitoring".

- Each of the above mentioned radionuclides can in principle be used. Particularly recommended however is technetium 99m (^{99m}Tc). The physical half-life of this radionuclide amounts to 6 hours and, together with the
- 40 fact that particularly gamma radiation is emitted, this

means a low radiation load for the patient. The relatively short half-life moreover has the clinical advantage that the examination can be repeated rapidly. In addition, this radionuclide is readily obtainable via the commercially available Mo-Tc-nuclide-generator.

It is found that peptide (fragments) labelled with technetium 99m can already be detected after 15 minutes at the site of the infection. The accumulation of for instance gallium 67 takes at least 24 hours. Owing to the very rapid localization of peptide (fragments) labelled with technetium 99m, a rapid diagnosis is possible. Furthermore, technetium 99m is mainly a γ emitter with a very small quantity of the much more harmful β radiation, so there is a relatively low radiation load for the patient. A more frequent administration is hereby possible. In addition, it has also been found that labelling with technetium 99m has no adverse influence on the action of the peptide (fragment). In laboratory animal experiments no adverse effects or changed external characteristics due to ^{99m}Tc -labelled peptide (fragments) have been found up to the present. In vitro studies have moreover shown that very high concentrations of the antimicrobial peptide (fragments) are not toxic for human body cells. Particular recommended therefore according to the invention as hybrid molecules are technetium 99m-labelled cationic peptides and fragments or derivatives thereof.

The peptide (fragments) according to the present invention demonstrate the infection itself and thus the location where the micro-organism is situated in the body. Known image-forming methods for detecting infections, such as X-ray, echography and the like are aimed at demonstrating morphological changes which are the result of an infection. It is very well possible however for the infection itself to have already disappeared, while the morphological change still exists. In that case the treatment of the infection with for instance antibiotics is simply continued while this is in fact no longer necessary. It is recommended in principle to cause a treatment with a determined antimicrobial agent to be as

short as possible in respect of the occurrence of resistances or allergies as a result of the agent. The peptide (fragments) according to the invention are infection-seeking and therefore make their way to the site of the infection itself and can also be made visible there. As soon as the infection has disappeared, this is shown by the fact that the peptide (fragment) no longer accumulates at the site of the (former) infection. The treatment can then be stopped. Using labelled peptides, infections can also be distinguished from inflammation processes. Infections occur when the body reacts to the presence of a foreign living organism. "Inflammation" is a general name for reactions of the body to foreign stimuli, such as particles, molecules, but also live bacteria. The peptide only reacts in the case of infections.

The invention further relates to combination preparations which, in addition to ubiquicidine and/or a peptide fragment thereof and/or a derivative thereof and/or a hybrid molecule, contain one or more other active components. Combinations with "classic" antibiotics or with antiviral or antifungal agents can for instance be envisaged.

The invention further relates to a method for labelling antimicrobial peptides, particularly cationic peptides, more particularly ubiquicidine and peptides derived therefrom and defensins. Such a method comprises of placing the peptide for labelling in contact with a tin(II) salt, a borohydride and a radioactive label in the presence of alkali, as described in Pauwels et al. (Nucl. Med. Biol. 20, 825-833 (1993)), but wherein the peptide is modified with MAG3 (mercapto-acetyl glycine-glycine-glycine). Prior to labelling the modified peptide is held at about 100°C for 10 minutes. Particularly in the case of small peptides or peptides carrying no sulphur groups, the MAG3 modification results in considerably higher labelling efficiencies.

The whole is stirred at a suitable temperature for a determined time, for instance 1 to 60 minutes, preferably 5 to 30 minutes. The temperature depends on the tempera-

ture sensitivity of the peptide, but will usually lie between room temperature and 40°C, and will preferably be about 37°C.

The tin(II) salt is preferably tin(II)pyrophosphate.
5 The borohydride is preferably sodium borohydride or potassium borohydride. The tin(II) salt and the borohydride are advantageously used in a ratio between 1:1 and 1:10, preferably 1:4 in quantities of respectively 0.5-5 µl and 2-10 µl. In preference 0.1 M sodium hydroxide is
10 used as alkali.

The radioactive label is advantageously ^{99m}Tc-per-technetate, but ¹⁸⁶Re-perrhenate can also be used. Standard solutions of such radioactive labels are commercially available. In the method according to the invention
15 0.05-0.5 ml, preferably 0.1 ml of such a solution is used.

A particularly advantageous manner of preparing ubiquicidine, and optionally the fragments, derivatives and hybrid molecules, is by means of transgenic animals.
20 For this purpose the method comprises of transforming an animal egg-cell with a gene construct which codes for the ubiquicidine, peptide fragment, derivative or hybrid molecule, regenerating a transgenic animal from the transformed egg-cell and isolating the ubiquicidine,
25 peptide fragment, derivative or hybrid molecule from a tissue or bodily fluid of the animal, for instance milk. The products can of course also be synthesized.

The present invention will further be elucidated on the basis of the accompanying examples, which are only
30 given by way of illustration but do not limit the invention. Reference is made in the examples to the following figures, in which:

- Figure 1 shows the amino acid sequence of ubiquicidine and derived peptides
35 Figure 2 shows the antimicrobial effect of ubiquicidine in respect of Klebsiella pneumoniae and Staphylococcus aureus
Figure 3 shows the effect of ubiquicidine (18-35) on herpes simplex virus infection of Vero cells

- Figure 4 shows the effect of ubiquicidine (18-35) on *Mycobacterium fortuitum*
- Figure 5 shows the effect of ubiquicidine (18-35) and ubiquicidine (18-29) on (antibiotic-resistant) *Staphylococcus aureus*
- Figure 6 shows the effect of ubiquicidine (18-35) and D-alanine-protected ubiquicidine (18-35) on *Klebsiella pneumoniae*
- Figure 7 shows the speed of ubiquicidine (18-35) and D-alanine-protected ubiquicidine (18-35) with which *Staphylococcus aureus* is eliminated
- Figure 8 shows the effect of ubiquicidine (18-35) and D-alanine-protected ubiquicidine (18-35) on (antibiotic-resistant) *Staphylococcus aureus*
- Figure 9 shows the effect of D-alanine-protected ubiquicidine (18-35) on (antibiotic-resistant) *Escherichia coli*
- Figure 10 is a scintigram of intraperitoneally administered ^{99m}technetium-labelled ubiquicidine (18-35) in a mouse infected with *Staphylococcus aureus*
- Figure 11 is a schematic view of the experimental infection and treatment of mice
- Figure 12 shows the accumulation of ^{99m}technetium-labelled ubiquicidine (18-35), ubiquicidine (1-18), defensins and human IgG in the thigh muscle infected with *Klebsiella pneumoniae*
- Figure 13 shows the accumulation of ^{99m}Tc-labelled ubiquicidine 18-35 in a nidus but not in inflammations
- Figure 14 shows the effect of ubiquicidine (18-35), ubiquicidine (1-18) and defensins on an experimental infection with *Staphylococcus aureus* and *Escherichia coli*
- Figure 15 shows the antimicrobial effect of ubiquicidine 29-41 and 18-35 and defensin-1 in mice

EXAMPLES

EXAMPLE 1

Antimicrobial action of ubiquicidine

1. Introduction

5 By means of gel filtration and reverse phase HPLC a peptide was isolated from the cytosol fraction of murine RAW 264.7 macrophages activated with interferon γ and cells of the human H292 bronchial epithelial cell line stimulated in different ways. The latter could be stimu-
10 lated with bacterial products (endotoxin, lipoteichoic acid), phorbol ester, and bronchial pathogens (Haemophilus influenzae, Streptococcus pneumoniae and para-influenza virus 3). The isolated peptide was called ubiquicidine.

15

2. Materials and method

2.1. Isolation of ubiquicidine

The method of isolating ubiquicidine from cytosol fractions of cells has been previously described for the
20 isolation of antimicrobial proteins from cell lysates and cell membrane fractions (Hiemstra et al. (1993) Infect. Immun. 61:3038-3046). The cells were cultured in RPMI 1640 medium with antibiotics and 10% heat-inactivated foetal calf serum. The cells were subsequently har-
25 vested, washed and resuspended in 10 mM sodium phosphate buffer (pH 7.4) enriched with a cocktail of protease inhibitors.

Using nitrogen cavitation, a cell lysate was obtained whereafter by means of ultracentrifugation at
30 27,000xg a membrane fraction and a cytosol fraction were obtained. The proteins in the cytosol fraction were extracted using 5% acetic acid and the acid extract was dialyzed and subsequently placed on a P60 column.

The fractions originating from this column were
35 tested for antimicrobial activity. The ubiquicidine-containing fractions were pooled and further separated by means of HPLC on a C18 column with heptafluorobutyric acid as "ion pairing molecule" in the eluent. The HPLC fractions were likewise tested for antimicrobial activity
40 and immunoreactivity using an antiserum against the N-

terminal part of the ubiquicidine. The pooled fractions contain pure ubiquicidine.

2.2. Biochemical characterization

5 The sequence of the N-terminal amino acids of purified ubiquicidine was determined by means of automated Edman degradation and a peptide sequencer 477A equipped with a PTH amino acid analyzer 120A (Applied Biosystems, Foster City, CA). The sequence results were subsequently
10 analysed using the GeneWorks software package (Intelli-genetics, Mountain View, CA). Molecular weight of ubiquicidine was determined using mass spectrometry (laser desorption time-of-flight mass spectrometry; Lasermat, Finnigan MAT LTD, Hemel Hempstead, UK). For the immuno-
15 logical identification of ubiquicidine use was made of a rabbit antiserum specific to the N-terminal part of ubiquicidine (ubiquicidine 1-18) and Western blotting.

2.3. Tests for antimicrobial activity in vitro

20 Different techniques were used to test for the antimicrobial activity of ubiquicidine and peptides derived therefrom. The gel overlay assay and the radial diffusion assay have been previously described (Hiemstra et al. (Infect. Immun. 63, 3038-3046 (1993))). In the
25 growth-killing curve determination which was used to investigate the IC 99% of the peptide, (mid-log or stationary phase) bacteria (Klebsiella pneumoniae (A) and Staphylococcus aureus (B) were exposed for 60 minutes at 37°C to increasing concentrations of the ubiquicidine,
30 whereafter the number of living bacteria in the suspension was determined using microbiological plate techniques (Colony Forming Units, CFU). As negative controls, bacteria were exposed to peptide 4 (a synthetic peptide derived from HIV glycoprotein 120), ubiquicidine (18-29)
35 or no peptide.

The results of such experiments are shown in CFUs in Figure 2.

3. Result

The ubiquicidine is a 6.7 kD ribosomal cationic peptide with a pI of 12.67. From sequence determination of the 18 N-terminal amino acids of the isolated peptide, it was found that these corresponded wholly with the N-terminal part of the S30 part of the expression product of the Finkel-Biskis-Reilly murine sarcoma associated ubiquitously expressed (FAU) gene which occurs inter alia in humans and mice. The molecular weight of the FAU S30 and the ubiquicidine were also found to correspond. It is therefore assumed that it is the same peptide.

From the determination of the in vitro antimicrobial action of ubiquicidine it was found that the ubiquicidine can kill micro-organisms very rapidly (< 10 minutes) and effectively (3-4 log reduction). Figure 2 shows mid-log Klebsiella pneumoniae (A) and Staphylococcus aureus (B), which were exposed for 60 minutes at 37°C to increasing concentrations of purified ubiquicidine in 10 mM sodium phosphate buffer. In the control incubations the bacteria multiplied a number of times (not shown). The minimal inhibiting concentration for said micro-organisms was found to lie between 0.08 and 0.16 µM, 1.5 µM ubiquicidine eliminates Klebsiella pneumoniae (A) almost completely, while the reduction in the number of Staphylococcus aureus (B) amounts to 2 log.

EXAMPLE 2

Antimicrobial action of peptide fragments

1. Introduction

A number of peptide fragments were derived from the native ubiquicidine and the antimicrobial activity thereof was determined.

2. Materials and methods

2.1. Production of synthetic peptides

Peptides were prepared using an Abimed AMS multiple peptide synthesizer and a fixed phase (tentagel AC, a polymer of polyethylene glycol spacer linked to a polystyrene matrix) (de Koster et al. (1995) J. Immunol. Methods 187:179-188). After completion of the synthesis

the peptide was released from the fixed phase using a trifluoroacetic acid water(19:1) mixture and the peptides were subsequently precipitated with an ether pentane(1:1) mixture at 20°C. After centrifugation the obtained peptides were dried at 40°C for 15 minutes. The peptides were subsequently dissolved in 10% acetic acid and concentrated by means of vacuum centrifugation. The purity of the peptides was determined using HPLC. An overview of the synthesized peptides derived from ubiquicidine is given in Figure 1. The antimicrobial activity of these peptide fragments was determined as described in Example 1 under 2.3.

2.2. Antimicrobial effect on Herpes Simplex Virus (HSV)

HSV was incubated for 60 minutes with increasing concentrations of the peptide fragment ubiquicidine (18-35) at 37°C. The virus preparation was subsequently added to Vero cells in diverse dilutions. After 3 days at 37°C the cytopathogenic effect of the virus on Vero cells was determined, with finally made it possible for the virus titre to be calculated. Figure 3 shows the result.

2.3. Antimicrobial effect on Mycobacterium fortuitum

About 10^6 Mycobacterium fortuitum were incubated for different intervals at 37°C with 14 μ M or 52 μ M ubiquicidine (18-35) and the number of living mycobacteria in the suspensions was then determined using microbiological techniques. The result is shown in Figure 4.

2.4. Antimicrobial effect on Staphylococcus aureus

About 10^6 bacteria of multidrug resistant Staphylococcus aureus (MRSA) and antibiotic-sensitive S. aureus were exposed for 60 minutes at 37°C to different concentrations of ubiquicidine (18-35), whereafter the number of living bacteria in the suspensions was determined microbiologically. As negative control high concentrations of ubiquicidine (18-29), peptide 4 and no peptide were used. The result is shown in Figure 5.

3. Results

Research into the effect of the different peptides on Klebsiella pneumoniae and Staphylococcus aureus demonstrated antimicrobial activity of ubiquicidine (1-18),
5 ubiquicidine (18-35) and ubiquicidine (29-41). The other peptides were found to be considerably less potent or inactive.

Figure 3 shows the results of the experiment with HSV. This shows that an increasing concentration of
10 peptide results in a decrease in the virus titre.

Figure 4 shows that ubiquicidine (18-35) kills M. fortuitum for a period of 3 hours, whereafter the peptide then shows a bacteriostatic effect. Repeated administration at 3 and 7 hours after the first dose results in
15 practically complete elimination of the mycobacteria. In the control incubations M. fortuitum was found to proliferate. In additional control experiments no indication was found for agglomeration of the mycobacteria due to ubiquicidine (18-35) (not shown).

20 Figure 5 shows that the peptide fragment ubiquicidine (18-35) results in a marked decrease in the number of CFUs of different Staphylococcus aureus strains.

EXAMPLE 3

25 Modified peptide fragments and their activity

1. Introduction

A number of the peptide (fragments) described in Example 2 was further modified in different ways by adding an extra D-alanine at the beginning and/or end as
30 protection against exopeptidase activity. The antimicrobial activity of several "derivatives" obtained in this manner was likewise determined.

2. Materials and methods

35 2.1. Production of modified peptides

D-alanine-protected peptides were prepared as described above (Example 2, ad 2.1) in this application.

2.2. Antimicrobial effect on Staphylococcus aureus

Staphylococcus aureus (5×10^5 bacteria) was exposed for different periods at 37°C to 7 μ M ubiquicidine (18-35) and D-alanine-protected ubiquicidine (18-35), whereafter the number of living bacteria in the suspension was quantified microbiologically.

In addition, different strains of (multidrug resistant) Staphylococcus aureus were incubated for 60 minutes at 37°C with increasing concentrations of D-alanine-protected and unprotected ubiquicidine (18-35), whereafter the number of living bacteria in the different suspensions was determined microbiologically.

2.3. Antimicrobial effect on Klebsiella pneumoniae

About 5×10^6 Klebsiella pneumoniae were exposed for 60 minutes at 37°C to increasing concentrations of ubiquicidine (18-35) and D-alanine-protected ubiquicidine (18-35) and the number of live bacteria was subsequently measured microbiologically.

2.4. Antimicrobial effect on Escherichia coli

About 10^6 antibiotic-resistant Escherichia coli and antibiotic-sensitive E. coli (parent strain of the resistant bacteria) were exposed for 60 minutes at 37°C to increasing concentrations of D-alanine-protected ubiquicidine (18-35), whereafter the number of living bacteria was determined microbiologically.

3. Results

Comparison of antimicrobial activities of the D-alanine-protected and the unprotected ubiquicidine (18-35) in respect of Klebsiella pneumoniae in vitro showed that the D-alanine-protected variant is much more potent in eliminating the bacteria than the unprotected ubiquicidine (18-35) peptide (Figure 6).

The maximum killing effect by both variants of ubiquicidine (ubiquicidine (18-35) and D-alanine-protected ubiquicidine (18-35)) on Staphylococcus aureus was achieved within 15 minutes (Figure 7). The speed of elimination of Staphylococcus aureus bacteria by the two types of ubiquicidine peptide is identical (Figure 7).

The results further demonstrated that the D-alanine-protected ubiquicidine kills (multidrug resistant) Staphylococcus aureus more effectively than the unprotected variant (Figure 8).

5 Very surprising is the observation that the D-alanine-protected ubiquicidine (18-35) can kill antibiotic-resistant Escherichia coli much more effectively than the antibiotic-sensitive parent strain of Escherichia coli (Figure 9). 1 μ M D-alanine-protected ubiquicidine reduces
10 the number of antibiotic-resistant bacteria to below the detection limit. A comparable antimicrobial effect relative to the parent strain is only achieved with 14 μ M of the peptide. This data shows that antibiotic-resistant bacteria can be eliminated very effectively by peptides
15 derived from ubiquicidine.

EXAMPLE 4

Peptide fragments labelled with Technetium 99m Tc

1. Introduction

20 A hybrid molecule was prepared by labelling the peptide fragments with the emitter 99m Tc. This example illustrates the manner of labelling according to the invention.

25 2. Materials and method

Labelling of peptide D (ubiquicidine (18-35)) and the D-alanine-protected ubiquicidine (18-35) with 99m Tc was performed using a method according to the invention. For this purpose 10 μ l of a MAG3-derived peptide solution
30 (2 mg/ml in 0.01 M sodium phosphate pH 3.0) was added to 2 μ l of a tin(II)pyrophosphate solution (0.5 mg/ml). Immediately thereafter 4 μ l of a 10 mg/ml KBH_4 solution (Sigma Chemical Company, St. Louis, Mo, US) in 0.1 M NaOH was added. After adding 0.1 ml of a 99m Tc sodium pertechnetate solution (20 MBq, Mallinckrodt Medical B.V.,
35 Petten, Netherlands) the mixture was stirred at room temperature for 30 minutes.

The radiochemical purity of peptides labelled with 99m Tc was determined after precipitation with 20% trichloroacetic acid (TCA), instantaneous thin-layer chromatog-
40

raphy (ITLC) and HPLC. Summarizing, this took place by analysing 20 μ l of a freshly prepared ^{99m}Tc -defensin-1 or ^{99m}Tc -IgG on a superose 12 column (Pharmacia, Upsala, Sweden), linked to an LKB Bromma HPLC 2249 chromatography pump (LKB, Upsala, Sweden) and an on-line NAI (Tl)-crystal-gamma-detection system (Raytest Steffi, Germany). The buffer which was used for analysing the ^{99m}Tc -labelled compounds was 14 mM sodium phosphate-buffered salt solution (PBS) pH 7.5 with a flow rate of 1 ml/minute. Labeling yields of ^{99m}Tc -labelled peptides were determined after precipitation with 20% TCA, HPLC analysis and ITLC analysis and were respectively more than 90%, more than 90% and more than 95%.

15 **EXAMPLE 5**

Accumulation of the labelled peptide at the site of infection

1. Introduction

In order to demonstrate that the peptide (fragment) according to the invention is infection-seeking, the localization of ^{99m}Tc -labelled peptides (ubiquicidine (18-35), ubiquicidine (1-18) and defensins in addition to IgG as control) was determined using a γ -camera.

25 2. Materials and method

Mice were infected intramuscularly with about 10^6 Staphylococcus aureus bacteria (ATCC 25923) and subsequently injected intraperitoneally with 25 μ g ^{99m}Tc -peptide. Mice were also injected intramuscularly with about 1×10^8 heat-killed (1 hour, 100°C) S. aureus, 1 μ g endotoxin or 100 ng phorbol myristate acetate (PMA) in order to cause sterile inflammations. At different points in time after injection of the peptide the radioactivity was measured in the circulation (heart), determined organs (liver, kidney, bladder and spleen) and in both thigh muscles using a γ -camera. Accumulation of the labelled peptide at the site of infection in the right thigh muscle is shown in Figure 10.

3. Results

The results showed a very short half-life of the peptides in the circulation, i.e. $t_{\text{half}} < 15$ minutes. The largest part of the injected labelled peptides ($> 60\%$) is removed via the liver, kidneys and bladder, but a part of the peptides (1-2% of the injected dose) arrives at the site of infection in the thigh muscle (Figure 10).

EXAMPLE 6

10 Antimicrobial activity in vivo

1. Introduction

The accumulation and antimicrobial activity in vivo of a number of ubiquicidine fragments was determined.

15 2. Materials and methods

2.1. Infection model

Reference is made to Figure 11 for a schematic view of the experimental infection and treatment of the mice. In summary, mice were infected intramuscularly in the right thigh muscle with about 10^6 bacteria and after 5 minutes injected intraperitoneally with about 25 μg (labelled) peptide. At different points in time after injection of the peptide the animals were killed and the right thigh muscle was removed, homogenized, and finally the number of bacteria in the homogenate was determined using microbiological plate techniques, or accumulation of the labelled peptide was determined by means of a γ -camera. This test involved animals which were normal and immunocompromised (injection with cyclophosphamide, "total body" radiation).

2.2. Infection-seeking effect of peptides according to the invention

Mice were infected in the right thigh muscle with Klebsiella pneumoniae and 25 μg $^{99\text{m}}\text{Tc}$ -labelled ubiquicidine (1-18) or ubiquicidine (18-35) was subsequently injected intraperitoneally. At different points in time after injection of the peptide the amount of activity in the right (test) and left (control) thigh muscle of the mouse was measured using a γ -camera. The results are

shown in Figure 12 as a ratio of the values in the right thigh muscle and the left thigh muscle, i.e. "target to non-target ratio". For the purpose of comparison the results for human defensin and IgG are also shown. The target to non-target ratios for infections and sterile inflammations were also compared (Figure 13).

2.3. Effect of antimicrobial peptides on experimental infections

Mice were infected in the right thigh muscle with Klebsiella pneumoniae (A) or Staphylococcus aureus (B). 5 minutes later, 25 µg ubiquicidine (18-35) or ubiquicidine (1-18) was injected intraperitoneally. 24 hours after administering of the peptide the animals were killed and the number of bacteria in the right thigh muscle was quantified microbiologically. As positive control, animals were injected intraperitoneally with human defensin and as negative control with the solvent of the antimicrobial peptides. The result is shown in Figure 14. The mice were also injected with 150 mg cyclophosphamide/kg body weight. Four days afterwards the animals were infected in the right thigh muscle with K. pneumonia and a day later different quantities of ubiquicidine (18-35), ubiquicidine (29-41) or defensin-1 were injected intravenously. Twenty-four hours after administering of the peptide the animals were killed and the number of bacteria in the right thigh muscle was quantified microbiologically. As control, normal animals were treated in identical manner. The result is shown in Figure 15.

30

3. Results

The accumulation of the tested peptides was found to be maximal 4 hours after administration and subsequently decreases in the course of time (Figure 12). It is notable that the maximum accumulation of ⁹⁹Tc-ubiquicidine (1-18) and ⁹⁹Tc-ubiquicidine (18-35) is reached much sooner than ⁹⁹Tc-IgG. This observation implies that ⁹⁹Tc-ubiquicidine peptides can be of importance for faster diagnostics of infections. Comparable results were found when the

35

⁹⁹Tc-peptide was administered intravenously 24 hours after infection.

The above stated pharmacological data shows that ubiquicidine (1-18) and ubiquicidine (18-35) accumulate rapidly in the infected thigh muscle. The results of our experiments into the effect of these peptides on the number of bacteria in the muscle demonstrate that ubiquicidine (18-35) eliminates bacteria more effectively than ubiquicidine (1-18) and defensins (Figure 12). These in vivo results correspond very well with the results of the in vitro experiments.

Figure 14 shows that particularly ubiquicidine (18-35) also has a marked bactericidal effect in vivo which is better than that of defensin.

The result in immunocompromised animals (Figure 15) shows that the bactericidal effect in vivo is determined by a direct bactericidal effect as well as by an immunomodulating effect.

CLAIMS

1. Use of ubiquicidine or optionally modified peptide fragments derived therefrom for the preparation of a drug for the treatment, diagnostics or prophylaxis of infections in humans and animals.

2. Peptide fragment derived from ubiquicidine and comprising a continuous series of at least 3 amino acids from the amino acid sequence of ubiquicidine: KVGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVPVPTFGKKKGPNA NS, with the exception of peptides having the amino acid sequence KVGSLARAGKVRGQTPKVAKQ or AGKVRGQTPKVAKQEKKKKKT.

3. Peptide fragment as claimed in claim 2 comprising a continuous series of at least 8 amino acids from the amino acid sequence of ubiquicidine: KVGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVPVPTFGKKKGPNA NS, with the exception of peptides having the amino acid sequence KVGSLARAGKVRGQTPKVAKQ or AGKVRGQTPKVAKQEKKKKKT.

4. Peptide fragment as claimed in claims 2 and 3 with one of the following amino acid sequences:

ubiquicidine (1-18)	KVGSLARAGKVRGQTPK
ubiquicidine (29-41)	TGRAKRRMQYNRR
ubiquicidine (18-29)	KVAKQEKKKKKT
ubiquicidine (18-35)	KVAKQEKKKKKTGRAKRR
ubiquicidine (29-35)	TGRAKRR
ubiquicidine (42-59)	FVNVPVPTFGKKKGPNANS
ubiquicidine (36-41)	MQYNRR

5. Derivative of ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a continuous series of at least 3, preferably at least 8 amino acids from the amino acid sequence of ubiquicidine: KVGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVPVPTFGKKKGPNA NS, which derivative has an amino acid sequence which is at least partly the reverse of the amino acid sequence of the corresponding original peptide (fragment) (so-called "(partial) reverse peptide").

6. Derivative of a ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a

continuous series of at least 3, preferably at least 8 amino acids from the amino acid sequence of ubiquicidine: KVGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVPVPTFGKKKGPNANS, wherein at least one of the amino acids from the original peptide (fragment) is replaced by a stereoisomer of that amino acid.

7. Derivative of ubiquicidine or of a peptide fragment derived from ubiquicidine and comprising a continuous series of at least 3, preferably at least 8 amino acids from the amino acid sequence of ubiquicidine: KVGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVPVPTFGKKKGPNANS, wherein the original amino acid chain is extended at one or both ends thereof with one or more groups, such as D-amino acids, protecting against degradation.

8. Derivative as claimed in claim 7 with the amino acid sequence:

D-A--KVAKQEKKKKKTGRAKRR--D-A

in which D-A represents D-alanine.

9. Hybrid molecule, comprising a cationic peptide with an antimicrobial action and/or a peptide fragment as claimed in claims 2-4 and/or a derivative thereof as claimed in claims 5-8, and one or more effector molecules.

10. Hybrid molecule as claimed in claim 9, wherein the effector molecule comprises an amino acid chain which is capable of binding to a micro-organism and/or substances secreted by micro-organisms or expressed on the surface thereof.

11. Hybrid molecule as claimed in claim 9, wherein the effector molecule is an endotoxin-binding peptide.

12. Hybrid molecule as claimed in claim 9, wherein the effector molecule is a detectable label.

13. Hybrid molecule as claimed in claim 12, wherein the detectable label is a radionuclide chosen from the group consisting of technetium 99m (Tc-99m), iodine 123 (I-123) and 131 (I-131), bromine 75 (B-75) and 76 (B-76), lead 203 (Pb-203), gallium 67 (Ga-67) and 68

(Ga-68), arsenic 72 (As-72), indium 111 (In-111), 113m (In-113m) and 114m (In-114m), ruthenium 97 (Ru-97), copper 62 (Cu-62), 64 (Cu-64) and 67 (Cu-67), iron 52 (Fe-52), manganese 52m (Mn-52m), chromium 51 (Cr-51),
5 ~~rhenium 186 (Re-186) and 188 (Re-188), terbium 161~~
(Tb-161), yttrium 90 (Y-90), fluorine 19 (F-19), sodium 23 (Na-23), phosphorus 31 (P-31), gadolinium 157 (Gd-157), manganese 55 (Mn-55), dysprosium 162 (Dy-162), chromium 52 (Cr-52) and iron 56 (Fe-56).

10 14. Hybrid molecule as claimed in claim 9, wherein the cationic peptide with antimicrobial activity is chosen from α - and β -defensins, ubiquicidine, protegrins, serprocidins, magainins, PR-39, cecropins.

15 15. A peptide fragment derived from ubiquicidine and comprising a continuous series of at least 3, preferably at least 8 amino acids from the amino acid sequence of ubiquicidine:
KVHGSLARAGKVRGQTPKVAKEKKKKKTGRAKRRMQYNRRFVNVPFTFGKKKGPNAN
20 NS for use in the diagnostics, prophylaxis or therapy of infections in humans and animals.

16. Peptide fragments as claimed in claim 3 for use in the diagnostics, prophylaxis or therapy of infections in humans and animals.

25 17. Derivatives as claimed in claims 5-8 for use in the diagnostics, prophylaxis or therapy of infections in humans and animals.

18. Hybrid molecules as claimed in claims 9-14 for use in the diagnostics, prophylaxis, therapy or monitoring of infections in humans and animals.

30 19. Peptide fragments as claimed in claim 15 or 16, derivatives as claimed in claim 17 or hybrid molecules as claimed in claim 18, wherein the microbial infections are caused by pathogenic Gram-positive (Staphylococcus aureus, Listeria monocytogenes including
35 antibiotic-resistant strains of S.aureus (also called Multidrug Resistant S.aureus (MRSA)) and Gram-negative ((antibiotic-resistant) Klebsiella pneumoniae, Escherichia coli, enterococci and Salmonella typhimurium)

bacteria, micro-organisms difficult to treat, such as Mycobacterium avium and Mycobacterium fortuitum, fungi, such as Candida albicans, Cryptococcus neoformans and Aspergillus fumigatis, viruses, in particular enveloped viruses, and parasites, such as Trypanosoma cruzi and Toxoplasma gondii.

20. Antimicrobial agent, comprising at least a suitable quantity of one or more active components chosen from ubiquicidine, peptide fragments derived from ubiquicidine and comprising a continuous series of at least 3, preferably at least 8 amino acids from the amino acid sequence of ubiquicidine:

KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVPFTFGKKKGPNANS, derivatives thereof as claimed in claims 5-8, hybrid molecules as claimed in claims 9-14, optionally in the presence of one or more suitable excipients.

21. Antimicrobial agent as claimed in claim 20 for use in therapy and prophylaxis in humans and animals.

22. Diagnostic agent, comprising a suitable quantity of one or more active components provided with a detectable label and chosen from ubiquicidine, peptide fragments derived from ubiquicidine and comprising a continuous series of at least 3, preferably at least 8 amino acids from the amino acid sequence of ubiquicidine: KVHGSLARAGKVRGQTPKVAKQEKKKKKTGRAKRRMQYNRRFVNVPFTFGKKKGPNANS, derivatives thereof as claimed in claims 5-8, hybrid molecules as claimed in claims 9-14.

23. Diagnostic agent as claimed in claim 20 for use in diagnostics and monitoring.

24. Method for labelling a cationic peptide with antimicrobial action, comprising of placing the peptide for labelling in contact with a tin(II) salt, a borohydride and a radioactive label in the presence of alkali, wherein the peptide is modified with MAG3 (mercapto-acetyl glycine-glycine-glycine).

25. Method as claimed in claim 24, wherein the tin(II) salt and the borohydride are respectively tin(II)pyrophosphate and sodium borohydride or potassium

borohydride, which are used in a ratio between 1:1 and 1:10, preferably 1:4, in quantities of respectively 0.5-5 μ l and 2-10 μ l, wherein the radioactive label is a standard solution of ^{99m}Tc -pertechnetate or ^{186}Re -perrhenate in a quantity of 0.05-0.5 ml, preferably 0.1 ml, wherein the alkali is sodium hydroxide and the alkali concentration is 0.5-5 M, preferably 0.1 M, and wherein the whole is stirred for 1 to 60 minutes, preferably 5 to 30 minutes at a temperature between room temperature and 40°C, and preferably at about 37°C.

26. Method for preparing ubiquicidine, peptide fragments derived from ubiquicidine and comprising a continuous series of at least 3, preferably at least 8 amino acids from the amino acid sequence of ubiquicidine: KVGSLARAGKVRGQTPKVAKEKKKKKTGRAKRRMQYNRRFVNVPVTFGKKKGPNA NS, derivatives thereof as claimed in claims 5-8, hybrid molecules as claimed in claims 9-14 by transforming an animal egg-cell with a gene construct which codes for the ubiquicidine, peptide fragment, derivative or hybrid molecule, regenerating a transgenic animal from the transformed egg-cell and isolating the ubiquicidine, peptide fragment, derivative or hybrid molecule from a tissue or bodily fluid of the animal, for instance milk.


1/17

PEPTIDE

Ubiquitin: (59aa, 6.654 kD)	KVHGSLARAGKVRGQTPK	VAKQEKKKKKTGRAKRRMQYNRRFVNVPVTFGKKKKGPNANS
(1-18, 2.153 kD)	KVHGSLARAGKVRGQTPK	
(29-41, 1.910 kD)	TGRAKRRMQYNRR	
(18-29, 1.643 kD)	KVAKQEKKKKKT	
(18-35, 3.477 kD)	KVAKQEKKKKKTGRAKRR	
(18-35, 3.656 kD)	AKVAKQEKKKKKTGRAKRRA	
(29-35, 953 D)	TGRAKRR	
(42-59, 2.213 kD)	FVNVPVTFGKKKKGPNANS	
(36-41, 957 D)	MQYNRR	

FIG.1

2/17

FIG. 2A

3/17





FIG. 2B

4/17

FIG. 3

5/17




FIG. 4

6/17




FIG. 5

7/17




FIG. 6

8/17




FIG. 7

9/17

Effect of ubi (18-35) and D-ala-protected ubi (18-35) on
S. aureus and antibiotic-resistant *S. aureus* (MRSA)




FIG. 8

10/17




FIG. 9

11/17

Infection model





FIG. 10

12/17

Accumulation of ^{99m}Tc -labelled ubiquitin (18-35) in the thigh muscle infected by staphylococcus aureus ATCC 25923 after intraperitoneal injection

FIG.11

13/17

Accumulation of ^{99m}Tc -labelled peptides in the thigh muscle infected by *Klebsiella pneumoniae* ATCC 43816






FIG. 12

Accumulation of 99 Tc-labelled ubiquitin 18-35 in an infection but not in inflammations



15/17

FIG. 14A

16/17

Effect of antimicrobial peptides on an experimental *Klebsiella pneumoniae* infection






FIG. 14B

17/17

Antimicrobial effect of ubiquidine 29-41 and 18-35 and defensin-1
in mice



Antimicrobial effect of ubiquidine 29-41 and 18-35 and defensin-1
in mice treated with cyclophosphamide

FIG.15

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

Antimicrobial peptides derived from ubiquicidine
the specification of which

(check one)

☐ is attached hereto.

☒ was filed on 29 May 1998 as PCT international application as
~~Application Serial No.~~ PCT/NL98/00311 and Serial No. 09/424,815 received
29 November 1999 and was amended on November 29, 1999
(if applicable)

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)			Priority Claimed	
<u>1006164</u>	<u>the Netherlands</u>	<u>29 May 1997</u>	<input checked="" type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No
<u> </u>	<u> </u>	<u> </u>	<input type="checkbox"/>	<input type="checkbox"/>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

(Application Serial No.)

(Filing Date)

(Status)
(patented, pending, abandoned)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

William H. Logsdon	22,132	Paul M. Reznick	33,059	Jesse A. Hirshman	40,016
Russell D. Orkin	25,363	John W. McIlvaine	34,219	James G. Porcelli	33,757
David C. Hanson	23,024	Michael I. Shamos	30,424	Kent E. Baldauf, Jr.	36,082
Richard L. Byrne	28,498	Blynn L. Shideler	35,034	Christian Schuster	43,908
Frederick B. Ziesenheim	19,438	Julie W. Meder	36,216	Dean E. Geibel	42,570
Kent E. Baldauf	25,826	Lester N. Fortney	38,141	Thomas J. Clinton	40,561
Barbara E. Johnson	31,198	Randall A. Notzen	36,882	Nathan J. Prepelka	43,016

Send Correspondence to:

Barbara E. Johnson, 700 Koppers Building, 436 Seventh Avenue, Pittsburgh PA 15219-1818

Direct Telephone calls to: (name and telephone number) Barbara E. Johnson (412) 471-8815

Full name of sole or first inventor

NIBBERING, Petrus Hendricus

Inventor's signature

Date

January 4, 2000

Residence

Voorhout, The Netherlands NLX

Citizenship

The Netherlands

Post office Address

Chopinlaan 5, NL-2215 SL Voorhout, The Netherlands

Full name of second joint inventor, if any

HIEMSTRA, Pieter Sicco

Second inventor's signature

Date

January 4, 2000

Residence

Leiderdorp, The Netherlands NLX

Citizenship

The Netherlands

Post office Address

Schelling 2, NL-2353 TE Leiderdorp, The Netherlands

(Supply similar information and signature for third and subsequent joint inventors.)

Full name of third joint inventor, if any

VAN DEN BARSELAAR, Maria Theodora

Third Inventor's signature

Date

January 4, 2000

Residence

Wassenaar, The Netherlands NLX

Citizenship

The Netherlands

Post Office Address

Rozeveldlaan 15, NL-2241 NR Wassenaar, The Netherlands

Full name of fourth joint inventor, if any

PAUWELS, Ernest Karel Jacob

Fourth inventor's signature

Date

January 4, 2000

Residence

Leiden, The Netherlands NLX

Citizenship

The Netherlands

Post Office Address

Van Beuningenlaan 10, NL-2334 CC Leiden, The Netherlands

Full name of fifth joint inventor, if any

FEITSMA, Rolf Ide Johannes

Fifth Inventor's signature

Date

January 4, 2000

Residence

Leiden, The Netherlands NLX

Citizenship

The Netherlands

Post Office Address

Kapteynstraat 43, NL-2313 RM Leiden, The Netherlands

Full name of sixth joint inventor, if any

Sixth inventor's signature

Date

Residence

Citizenship

Post Office Address

(Supply similar information and signature for subsequent joint inventors.)